Aldosterone Inhibitor Leaders Gather at Bank of America Securities Health Care Conference in Las Vegas
In Las Vegas on May 14-16, 2024, the Bank of America Securities Health Care Conference will take place. Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that focuses on developing medicines to treat hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone, has announced that management will be participating in a fireside chat at the conference.
The fireside chat featuring Mineralys Therapeutics will be held on Wednesday, May 15, 2024, at 5:00pm PDT. A live webcast of the event will be accessible on the company’s website at www.mineralystx.com under “News and Events” in the Investor Relations section. Additionally, a replay of the fireside chat will be available on the website for approximately 90 days after the event.
Mineralys Therapeutics is dedicated to developing innovative solutions for cardiorenal conditions affected by dysregulated aldosterone. Their lead product candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor designed to treat these conditions. The company was founded by Catalys Pacific and is based in Radnor, Pennsylvania. For more information about Mineralys Therapeutics and their products, please visit their website at https://mineralystx.com or follow them on LinkedIn and Twitter.
For investor relations inquiries, please contact investorrelations@mineralystx.com. For media relations, reach out to Tom Weible at Elixir Health Public Relations by phone at (1) 515-707-9678 or email at tweible@elixirhealthpr
